DHA for Brain Fitness? Mixed Results
A paper in last week’s JAMA reports on a clinical trial of docosahexaenoic acid (DHA) in preventing cognitive decline in patients with Alzheimer’s disease. DHA is a component of fish oil supplements that have been recommended for the prevention of heart disease and, possibly, to prevent aging-related cognitive decline.
Results of the overall study were negative – DHA at a dose of 2 grams a day didn’t slow how much patients’ cognitive abilities declined over 18 months.
One finding of the study has been largely ignored in media reports. In a planned subgroup analysis, though, patients treated with DHA and who did not have the ApoE 4 allele had slower cognitive decline. ApoE 4 is a gene that has been associated with greater risk for having Alzheimer’s disease. It may be related to how fatty substances in the body are used by the body.
Although the findings of the main trial are negative, one subgroup may have benefited from DHA treatment.
This study thus adds to a series of studies based on observations that people who take vitamins, nonsteroidal anti-inflammatory drugs, and fish oil supplements have lower risks for Alzheimer’s disease. The logic of the trials has been to evaluate things associated with lower risk as treatments, but none has turned out to be effective.
Click here to read the full article.
Reference:
Quinn JF et al (2010). Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease. JAMA, 304, 1903-1911.
